Stock comparison
AstraZeneca
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AZN
AstraZeneca
Market cap
$290.06B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AZN | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 72B | RMD |
| Benjamin Graham | 73B | 75B | RMD |
| Philip Fisher | 64C | 75B | RMD |
| Peter Lynch | 63C | 58C | AZN |
| Joel Greenblatt | 51C | 47D | AZN |
| Charlie Munger | 62C | 69B | RMD |
| Terry Smith | 60D | 73B | RMD |
Side-by-side metrics
| Metric | AZN | RMD |
|---|---|---|
| Market cap | $290.06B | $30.18B |
| P/E (TTM) | 27.6x | 19.6x |
| EV/EBIT | 23.0x | 17.1x |
| ROIC (TTM) | 12.88% | 19.63% |
| Gross margin | 79.71% | 61.69% |
| Net margin | 17.19% | 27.44% |
| Revenue CAGR 5y | 11.93% | 12.64% |
| EPS CAGR 5y | 2.01% | 30.73% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 1.7% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AZN leads on
- Market cap$290.06Bvs $30.18B+90%
- EPS CAGR 5y2.01%vs 30.73%+85%
- Dividend yield1.7%vs 1.14%+33%
- Gross margin79.71%vs 61.69%+23%
RMD leads on
- Debt / Equity0.1xvs 0.7x+82%
- Net margin27.44%vs 17.19%+37%
- ROIC (TTM)19.63%vs 12.88%+34%
- P/E (TTM)19.6xvs 27.6x+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.